Antiplatelet and Anticoagulation    Combined fibrinolysis using reduced-dose alteplase plus abciximab with immediate rescue angioplasty versus primary angioplasty with adjunct use of abciximab for the treatment of acute myocardial infarction: Asia-Pacific Acute Myocardial Infarction Trial ( Catheter Cardiovasc Interv (2004);62:445-52 A. Wong, et al. Effects of a novel platelet nitric oxide donor (LA816), aspirin, clopidogrel, and combined therapy in inhibiting flow- and lesion-dependent thrombosis in the porcine ex vivo model Circulation (2004);110:1686-93 G. Vilahur, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the ongoing tirofiban in myocardial infarction evaluation (On-TIME) trial Eur Heart J (2004);25:837-46 A. W. van't Hof, et al. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease Jama (2004);292:1867-74 H. Tran and S. S. Anand Impact of stenting and abciximab in patients with diabetes mellitus undergoing primary angioplasty in acute myocardial infarction (the CADILLAC trial) Am J Cardiol (2005);95:1-7 T. D. Stuckey, et al. Antithrombotic therapy in patients with saphenous vein and internal mammary artery bypass grafts: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest (2004);126:600S-608S P. D. Stein, et al. DECOPI (DEsobstruction COronaire en Post-Infarctus): a randomized multi-centre trial of occluded artery angioplasty after acute myocardial infarction Eur Heart J (2004);25:2187-94 P. G. Steg, et al. Rofecoxib use increases acute myocardial infarction risk Circulation (2004);109:e9039-40 R. SoRelle Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction Am Heart J (2004);147:993-8 P. R. Sinnaeve, et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study J Am Coll Cardiol (2004);43:2183-90 M. L. Simoons, et al. Tirofiban therapy for patients with acute coronary syndromes and prior coronary artery bypass grafting in the PRISM-PLUS trial Am J Cardiol (2004);93:843-7 S. J. Servoss, et al. Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention Am J Cardiol (2004);94:623-5 J. Saw, et al. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy J Am Coll Cardiol (2004);44:1194-9 J. Saw, et al. Implications of upstream glycoprotein IIb/IIIa inhibition and coronary artery stenting in the invasive management of unstable angina/non-ST-elevation myocardial infarction: a comparison of the Thrombolysis In Myocardial Infarction (TIMI) IIIB trial and th Circulation (2004);109:874-80 M. S. Sabatine, et al. Improved speed and stability of ST-segment recovery with reduced-dose tenecteplase and eptifibatide compared with full-dose tenecteplase for acute ST-segment elevation myocardial infarction J Am Coll Cardiol (2004);43:549-56 M. T. Roe, et al. Approach to "aspirin allergy" in cardiovascular patients Circulation (2004);110:e1-4 S. Ramanuja, et al. Aspirin dose and six-month outcome after an acute coronary syndrome J Am Coll Cardiol (2004);43:972-8 M. J. Quinn, et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients J Am Coll Cardiol (2004);43:979-84 F. M. Pulcinelli, et al. Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest (2004);126:576S-599S J. J. Popma, et al. Differential treatment benefit of platelet glycoprotein IIb/IIIa inhibition with percutaneous coronary intervention versus medical therapy for acute coronary syndromes: exploration of methods Circulation (2004);109:641-6 K. S. Pieper, et al. Long-term outcome in elderly patients with chronic angina managed invasively versus by optimized medical therapy: four-year follow-up of the randomized Trial of Invasive versus Medical therapy in Elderly patients (TIME) Circulation (2004);110:1213-8 M. Pfisterer Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview Jama (2004);292:89-96 J. L. Petersen, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy Circulation (2004);109:1476-81 D. A. Payne, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology Eur Heart J (2004);25:166-81 C. Patrono, et al. Five-year outcome of patients with acute myocardial infarction enrolled in a randomised trial assessing the value of abciximab during coronary artery stenting Eur Heart J (2004);25:1635-40 G. Ndrepepa, et al. Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS) Am J Cardiol (2004);94:774-6 D. A. Morrow, et al. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis Jama (2004);292:362-6 G. Montalescot, et al. Frequency of nonresponse antiplatelet activity of clopidogrel during pretreatment for cardiac catheterization Am J Cardiol (2004);93:456-8 J. E. Mobley, et al. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting Circulation (2004);109:2203-6 P. A. Merlini, et al. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel Circulation (2004);110:3627-35 J. Mehilli, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction Circulation (2004);109:3171-5 S. Matetzky, et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study Catheter Cardiovasc Interv (2004);61:163-70 J. L. Martin, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial Jama (2004);292:696-703 A. M. Lincoff, et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial) Am J Cardiol (2004);93:1092-6 A. M. Lincoff, et al. Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest (2004);126:287S-310S M. N. Levine, et al. Administration of eptifibatide to acute coronary syndrome patients receiving enoxaparin or unfractionated heparin: effect on platelet function and thrombus formation J Am Coll Cardiol (2004);43:966-71 E. I. Lev, et al. Assessment of anticoagulation using activated clotting times in patients receiving intravenous enoxaparin during percutaneous coronary intervention Catheter Cardiovasc Interv (2004);61:52-5 M. Lawrence, et al. Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study J Am Coll Cardiol (2004);43:276-83 H. Kunichika, et al. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment Am Heart J (2004);148:582-9 M. W. Kruse and J. J. Lee The effects of nonselective non-aspirin non-steroidal anti-inflammatory medications on the risk of nonfatal myocardial infarction and their interaction with aspirin J Am Coll Cardiol (2004);43:985-90 S. E. Kimmel, et al Optimal suppression of thromboxane A(2) formation by aspirin during percutaneous transluminal coronary angioplasty: no additional effect of a selective cyclooxygenase-2 inhibitor J Am Coll Cardiol (2004);43:526-31 D. Kearney, et al. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy Circulation (2004);110:1916-9 A. Kastrati, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel N Engl J Med (2004);350:232-8 A. Kastrati, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial Jama (2004);291:947-54 A. Kastrati, et al. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials Am Heart J (2004);147:457-62 D. E. Kandzari, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization J Am Coll Cardiol (2004);44:2133-6 D. E. Kandzari, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after coronary stent implantation Am Heart J (2004);147:E15 C. P. Juergens, et al. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation J Am Coll Cardiol (2004);44:1408-14 T. Inoue, et al. Effect of fixed low-dose warfarin added to aspirin in the long term after acute myocardial infarction; the LoWASA Study Eur Heart J (2004);25:232-9 J. Herlitz, et al. Antithrombotic therapy for coronary artery disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest (2004);126:513S-548S R. A. Harrington, et al. Use of abciximab prior to primary angioplasty in STEMI results in early recanalization of the infarct-related artery and improved myocardial tissue reperfusion - results of the Austrian multi-centre randomized ReoPro-BRIDGING Study Eur Heart J (2004);25:2125-33 M. Gyongyosi, et al. Outcome of acute ST-segment elevation myocardial infarction in diabetics treated with fibrinolytic or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: lessons from the GUSTO V trial J Am Coll Cardiol (2004);43:542-8 H. S. Gurm, et al. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study Lancet (2005);365:475-81 D. J. Graham, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting Eur Heart J (2004);25:1898-902 O. Gorchakova, et al. Aspirin sensitivity: implications for patients with coronary artery disease Jama (2004);292:3017-23 R. R. Gollapudi, et al. Co-administration of nitric oxide-aspirin (NCX-4016) and aspirin prevents platelet and monocyte activation and protects against gastric damage induced by aspirin in humans J Am Coll Cardiol (2004);44:635-41 S. Fiorucci, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial Jama (2004);292:45-54 J. J. Ferguson, et al. Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction J Am Coll Cardiol (2004);44:1187-93 N. M. Ernst, et al. Long-term clopidogrel therapy after percutaneous coronary intervention in PCI-CURE and CREDO: the "Emperor's New Clothes" revisited Eur Heart J (2004);25:720-2 P. Eriksson Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI) Am Heart J (2004);148:378-85 C. Di Mario, et al. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial management strategy: results from the A phase of the A-to-Z trial Eur Heart J (2004);25:1688-94 J. A. de Lemos, et al. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function Am J Cardiol (2004);94:35-9 G. B. Danzi, et al. Safety of a high bolus dose of tirofiban in patients undergoing coronary stent placement Catheter Cardiovasc Interv (2004);61:179-84 G. B. Danzi, et al. Predictors of and outcomes of early thrombosis following balloon angioplasty versus primary stenting in acute myocardial infarction and usefulness of abciximab (the CADILLAC trial) Am J Cardiol (2004);94:983-8 G. Dangas, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel J Am Coll Cardiol (2004);43:162-8 M. Dalby, et al. Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3) Am J Cardiol (2004);94:279-83 J. P. Curtis, et al. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction J Am Coll Cardiol (2004);44:305-12 C. O. Costantini, et al. Subcutaneous enoxaparin with early invasive strategy in patients with acute coronary syndromes Am Heart J (2004);147:655-61 J. P. Collet, et al. Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes Circulation (2004);110:2361-7 J. P. Collet, et al. Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis Eur Heart J (2004) M. J. Claeys, et al. Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention Am J Cardiol (2004);94:789-92 E. Cheneau, et al. Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J Am Coll Cardiol (2004);43:1122-6 W. H. Chen, et al. Volumetric analysis of in-stent intimal hyperplasia in diabetic patients treated with or without abciximab: results of the Diabetes Abciximab steNT Evaluation (DANTE) randomized trial Circulation (2004);109:861-6 A. J. Chaves, et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial Jama (2004);292:55-64 M. A. Blazing, et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention Catheter Cardiovasc Interv (2004);62:186-92 F. Bellandi, et al. Invasive therapy along with glycoprotein IIb/IIIa inhibitors and intracoronary stents improves survival in non-ST-segment elevation acute coronary syndromes: a meta-analysis and review of the literature Am J Cardiol (2004);93:830-5 A. A. Bavry, et al. Abciximab-supported infarct artery stent implantation for acute myocardial infarction and long-term survival: a prospective, multicenter, randomized trial comparing infarct artery stenting plus abciximab with stenting alone Circulation (2004);109:1704-6 D. Antoniucci, et al. Pharmacoinvasive therapy: the future of treatment for ST-elevation myocardial infarction Circulation (2004);109:2480-6 E. M. Antman and F. Van de Werf High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability Eur Heart J (2004);25:1903-10 D. J. Angiolillo, et al.